# EDGAR Filing Document

**Accession Number:** 0001828253
**File Stem:** 0001104659-23-005438
**Filing Date:** 2023-1
**Character Count:** 3432
**Document Hash:** f80a74510ef30975e3a27c5f928888be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-005438.hdr.sgml**: 20230120

**ACCESSION NUMBER**: 0001104659-23-005438

**CONFORMED SUBMISSION TYPE**: 6-K/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230120

**FILED AS OF DATE**: 20230120

**DATE AS OF CHANGE**: 20230120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evaxion Biotech A/S
- **CENTRAL INDEX KEY:** 0001828253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39950
- **FILM NUMBER:** 23541561

**BUSINESS ADDRESS:**
- **STREET 1:** BREDGADE 34E
- **CITY:** COPENHAGEN K
- **STATE:** G7
- **ZIP:** 1260
- **BUSINESS PHONE:** 4531262615

**MAIL ADDRESS:**
- **STREET 1:** BREDGADE 34E
- **CITY:** COPENHAGEN K
- **STATE:** G7
- **ZIP:** 1260

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K/A**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO SECTION 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2023**

**Commission File Number: 001-39950**

**Evaxion Biotech A/S**

**(Exact Name of Registrant as Specified in Its Charter)**

**Dr. Neergaards Vej 5f**

**DK-2970 Hoersholm**

**Denmark**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

**EXPLANATORY NOTE**

This Amendment to the Report on Form 6-K originally filed with the Securities and Exchange Commission on January 19, 2023 (the "Form 6-K"), is being filed solely for the purposes of adding the following language related to the incorporation by reference of the information contained in the Form 6-K into the registration statements set forth in such added language**.** 

**INCORPORATION BY REFERENCE**

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S's registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132) and on Form F-1 (File No. 333-266050), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Other than as expressly set forth above, this Form 6-K/A does not, and does not purport to, amend, update or restate the information in any other item of the Form 6-K, including any exhibits thereto, or reflect any events that have occurred after the Form 6-K was originally filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Evaxion Biotech A/S** | **Evaxion Biotech A/S** |
| Date: January 20, 2023 | By: | /s/ Bo Karmark |
|  |  | Bo Karmark<br> Chief Financial Officer |

---